Business · 19/12/2014Updated: 10/17/2026 · 1 min read
FDA Hosts Public Conference on Serious Drug-Induced Liver Injury
Summary
The FDA, in collaboration with C-Path and PhRMA, is hosting a public conference to discuss strategies for detecting and assessing drug-induced liver injury, with the goal of improving diagnosis and patient outcomes.
Original source language: Federal Register — Food and Drug AdministrationOpen original release →